Paris: Following the adoption of a positive opinion by the European Medicines Agency's (EMA) Committee for Medicinal Products ...
Primary results of phase 3 AURIGA study indicated that dual maintenance therapy after transplant led to improved outcomes.
Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.
Zacks.com on MSN4d
Pharma Stock Roundup: JNJ's Q4 Earnings, FDA Nod to AZN, Daiichi DrugJ&J JNJ announced fourth-quarter and full-year 2024 results, starting the earnings season for the drug and biotech sector.
Failed to fetch dynamically imported module: https://sg.finance.yahoo.com/assets/_app/immutable/nodes/100.C0JpamNs.js ...
The latest decision makes Sanofi's Sarclisa the first anti-CD38 therapy for transplant-ineligible patients with front-line ...
Sanofi (NASDAQ:SNY) has received EU regulatory approval for its drug Sarclisa for the treatment of newly diagnosed multiple myeloma patients. The drug was approved for use in combination with a ...
Sanofi’s Sarclisa has been approved by the European Union as the first anti-CD38 therapy in combination with VRd to treat adult patients with newly diagnosed multiple myeloma who are ineligible for ...
Sanofi’s Sarclisa has been approved by the European Union as the first anti-CD38 therapy in combination with VRd to treat adult patients with newly diagnosed multiple myeloma who are ineligible for ...
Sanofi’s Sarclisa (isatuximab) has been approved by the European Commission (EC) to treat adults with newly diagnosed ...
Sanofi secures EU approval for Sarclisa with VRd for newly diagnosed multiple myeloma patients ineligible for stem cell ...
The US FDA has removed the clinical hold on a trial of Cialis (tadalafil) by Sanofi's consumer healthcare business, Opella.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback